成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Wuhan Jingkangen Biomedical Technology Co., Ltd

Firmenname:Wuhan Jingkangen Biomedical Technology Co., Ltd
Telefon:13720134139 +86 -0-15871494362
E-Mail:orders@jknbiochem.com
Nationalit?t:China
URL: www.jknbiochem.com
Produkte insgesamt:5821
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59

Produktkatalog

Sulesomab167747-19-5
Research Grade Cc49
Motavizumab677010-34-3
Ethyl 2-(4-hydroxyphenyl)-4-methylthiazole-5-carboxylate161797-99-5C13H13NO3S
Olaparib763113-22-0C24H23FN4O3
Eculizumab219685-50-4
Hu1D10267227-08-7
palivizumab188039-54-5
Ethyl 2-(3-formyl-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate161798-03-4C18H21NO4S
Ethyl 2-(3-formyl-4- hydroxyphenyl)-4- methylthiazole-5-carboxylate161798-01-2C14H13NO4S
Ranibizumab347396-82-1C11H12N2O2
Basiliximab179045-86-4
Ibrutinib (PCI-32765)936563-96-1C25H24N6O2
ApreMilast608141-41-9C22H24N2O7S
Lambrolizumab1374853-91-4
4-hydroxythiobenzamide25984-63-8C7H7NOS
Omalizumab242138-07-4
Lorvotuzumab Mertansine1008106-64-6
NEW PRODUCTS INTRODUCTION
Foravirumab944548-38-3
Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate160844-75-7C18H20N2O3S
Diisopropylamine dichloroacetateDichloressigs?ure, Verbindung mitN-(1-Methylethyl)-2-propanamin(1:1)660-27-5C8H17Cl2NO2
Pascolizumab331243-22-2
Siplizumab288392-69-8
Ruplizumab220651-94-5
Visilizumab219716-33-3
Vonoprazan881681-00-1C17H16FN3O2S
Research Grade Fontolizumab326859-36-3
Ixekizumab1143503-69-8
dupilumab1190264-60-8
(S)-1-(4-Fluorophenyl)-5-(2-oxo-4-phenyloxazolidin-3-yl)pentane-1,5-dione189028-93-1C20H18FNO4
Narsoplimab2108782-45-0
Neratinib688387-09-6C30H29ClN6O3
Igovomab171656-50-1
4,4-dimethyl-3,5,8- trioxabicyclo[5.1.0]octane57280-22-5C7H12O3
Pomalidomide19171-19-8C13H11N3O4
Topiroxostat577778-58-6C13H8N6
TocilizuMab375823-41-9C14H12O3
Bevacizumab216974-75-3C6638H10160N1720O2108S44
Dacliximab152923-56-3
Imciromab126132-83-0
Pertuzumab380610-27-5C17H27NO2
Matuzumab339186-68-4
Carbazochrome Sodium SulfonateNatrium-5-(carbamoylhydrazono)-2,3,5,6-tetrahydro-1-methyl-6-oxo-1H-indol-2-sulfonat51460-26-5C10H17N4NaO8S
nimotuzumab828933-51-3
Crisaborole906673-24-3C14H10BNO3
Nivolumab946414-94-4
Sarilumab1189541-98-7
1-Methylcyclopropanecarboxylic acid1-Methylcyclopropancarbonsure6914-76-7C5H8O2
Amatuximab931402-35-6
Febuxostat144060-53-7C16H16N2O3S
Bavituximab648904-28-3
Abciximab143653-53-6
Rafivirumab944548-37-2
Research Grade Cedelizumab156586-90-2
Gemtuzumab220578-59-6
Sevirumab
Research Grade cT84.66
(R)-(-)-2,2-dimethyl-1,3-dioxolane-4-methanol14347-78-5C6H12O3
Lymphocide205923-57-5
Milatuzumab899796-83-9
Odulimomab159445-64-4
(4S)-3-[(5S)-5-(4-Fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one189028-95-3C20H20FNO4
Abemaciclib1231929-97-7C27H32F2N8
EFALIZUMABUM214745-43-4
Mitumomab216503-58-1
Labetuzumab219649-07-7
Ezetimibe163222-33-1C24H21F2NO3
Lintuzumab166089-32-3
Naptumomab Estafenatox676258-98-3
Tadocizumab339086-80-5
Alemtuzumab216503-57-0
Tositumomab208921-02-2
cantuzumab mertansine400010-39-1
Ethyl 2-(3-cyano-4-hydroxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate161798-02-3C14H12N2O3S
Gevokizumab1129435-60-4
Apalutamide956104-40-8C21H15F4N5O2S
Oregovomab213327-37-8
Erlotinib Hydrochloride183321-74-6C22H23N3O4
Siltuximab541502-14-1
Entecavir hydrate209216-23-9C12H17N5O4
Research Grade Tecnemab
Edobacomab141410-98-2
Iodine (131I) Derlotuximab Biotin340013-96-9
Gavilimomab244096-20-6
Research Grade T10B9.1A-31
Abagovomab792921-10-9
Edrecolomab156586-89-9
Inolimomab152981-31-2
Arcitumomab154361-48-5
Pexelizumab219685-93-5
Nofetumomab165942-79-0
Enlimomab142864-19-5
Capromab145464-28-4C10H15N5O11P2
Natalizumab189261-10-7C40H55N7O11S
Satumomab144058-40-2
Biciromab138783-13-8
Research Grade Afelimomab156227-98-4
mepolizumab196078-29-2
Research Grade Immurait-Ll2Mab
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59
Copyright 2019 ? ChemicalBook. All rights reserved